Allied Market Research

2026

Relapsing-remitting Multiple Sclerosis Market

Relapsing-Remitting Multiple Sclerosis Market (2023-2032)

by Treatment (Immunomodulating Drugs, NrF2 Activators, Interferons, Others), by Route of Administration (Oral, Intravenous) and, by End User (Hospitals, Clinics, Others)

LS : Therapeutics

  • Feb 2026

  • Pages: NA

  • Tables: NA

  • Charts: NA

Select an option
Cloud Access (30% Off) $3,690 $2,583
Business User License (30% Off) $5,820 $4,074
Enterprise License (30% Off) $9,870 $6,909
Library Membership (15% Off) $1,175 $999
Enquiry Now
Author's: | Eswara Prasad
Publish Date:
Enquire Before Buying Customization Request Speak with Analyst